Compare STAG & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STAG | RYTM |
|---|---|---|
| Founded | 2010 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1B | 5.8B |
| IPO Year | 2010 | 2017 |
| Metric | STAG | RYTM |
|---|---|---|
| Price | $37.64 | $104.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $39.67 | ★ $131.14 |
| AVG Volume (30 Days) | ★ 1.4M | 526.9K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.07% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $845,184,000.00 | N/A |
| Revenue This Year | $8.59 | $55.34 |
| Revenue Next Year | $9.28 | $86.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.14 | N/A |
| 52 Week Low | $34.40 | $74.50 |
| 52 Week High | $42.61 | $122.20 |
| Indicator | STAG | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 50.79 | 41.18 |
| Support Level | $37.26 | $99.14 |
| Resistance Level | $38.20 | $111.56 |
| Average True Range (ATR) | 0.44 | 4.11 |
| MACD | 0.18 | -1.27 |
| Stochastic Oscillator | 90.58 | 7.03 |
Stag Industrial Inc is a REIT focused on the acquisition, ownership, development, and operation of industrial properties throughout the United States. Its platform is designed to (i) identify properties for acquisition that offer attractive returns across CBRE-EA Tier 1 industrial real estate markets, industries, and tenants, (ii) provide growth through the ownership of high-quality assets, property management and pursuit of acquisitions in an attractive opportunity set, and (iii) capitalize its business appropriately given the characteristics of its assets. The majority of its portfolio is single-tenant industrial properties throughout the United States. The company derives the majority of its rental revenue from its facilities located in Midwestern and Eastern U.S. cities.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.